摘要
目的幽门螺杆菌(Helicobacterpylori,Hp)是慢性胃炎、消化性溃疡的主要致病因素之一。本研究旨在通过对奥美拉唑(OME)和呋喃唑酮(FZ)联合用药的疗效观察以寻求一种有效、方便的疗法。方法病例选择:经胃镜检查确诊的慢性胃炎或十二指肠球部溃疡且Hp检测阳性的患者,经过纳入标准及排除标准的筛选而进入研究。分组治疗:病例随机分为三个治疗组,治疗组1(23人):OME20mgqd+FZ0.2gbid;治疗组2(25人):OME20mgqd+FZ0.2gtid;治疗组3(26人):OME20mgbid+FZ0.2gtid,疗程均为7天。其中十二指肠球部溃疡病人OME按各自剂量再服一周。停药四周后做13C-尿素呼气试验。结果74例患者进入研究。治疗组1有22人完成全疗程,根除率864%;治疗组2为18人,根除率833%;治疗组3为19人,根除率789%。治疗组2、3(FZ02gtid)与治疗组1(FZ02gbid)之间根除率的差异无显著意义,但不良反应发生率明显增加。结论本研究显示方案一不良反应发生率低,依从性好,疗效达到864%;依从性是影响根除率高低的重要因素;体外试验显示Hp对呋喃唑酮?
Aim Helicobacter pylori(Hp)
is one of the main pathogenic factors of chronic gastritis and peptic ulcer.This study is to
evaluate the clinical effect of dual therapy of OME (omeprazol)plus FZ(furazolidone) and
consequently to find an effective and convenient medication for eradication of Hp. Methods
Patients: The Hp postitive patients with chronic gastritis or duodenal ulcer confirmed by
gastroscopy were enrolled in this research according to the eligibility criteria. Intervention:
Totally 74 patients were finally selected and randomly allocated into 3 groups.The 7-day
medication for Group 1(23 cases )was OME 20 mg qd+FZ 0.2 g bid,Group 2(25 cases) OME 20
mg qd+FZ 0.2 tid and Group 3 (26 cases)OME 20 mg bid+FZ 0.2 tid.The patients with duodenal
ulcer took OME for one more week.The 13C-urea breath test for Hp infection was performed 4
weeks after the end of intervention. Results There were finally 22 patients in Group 1 who
completed the interventional protocol,18 in group 2,and 19 in group 3.Comparing with the
eradication rate of 86.4% of Group 1, the eradication rates of Group 2 and 3(83.3% and 78.9%
respectively)has no significant difference;however,the adverse-effect rates of the latter
two(32.0% and 23.1%,respectively)were much higher than that of Group 1(8.7%).HZ]Conclusion It
showed that the therapy of OME 20 mg qd+FZ 0.2 bid could achieve the Hp eradication rate of
86.4% with low adverse-effect rate and good compliance.It was also found that the compliance
was important for the eradication of Hp.The Hp strains in this research were all sensitive for FZ.
出处
《胃肠病学和肝病学杂志》
CAS
1999年第2期120-123,共4页
Chinese Journal of Gastroenterology and Hepatology